Theravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50-Day Moving Average - Should You Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.61 and traded as high as $10.80. Theravance Biopharma shares last traded at $10.75, with a volume of 155,522 shares trading hands.

Wall Street Analyst Weigh In

TBPH has been the topic of a number of recent analyst reports. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research report on Tuesday. Finally, HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $14.50.

Theravance Biopharma Stock Performance

The stock has a 50-day simple moving average of $9.74 and a 200 day simple moving average of $9.47. The stock has a market capitalization of $531.50 million, a P/E ratio of -9.01 and a beta of -0.09.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. Equities analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at $3,330,342. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of TBPH. Rhumbline Advisers raised its position in shares of Theravance Biopharma by 3.8% during the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after acquiring an additional 2,293 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after purchasing an additional 174,451 shares during the last quarter. Jane Street Group LLC increased its holdings in Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after purchasing an additional 88,540 shares during the last quarter. Park West Asset Management LLC lifted its stake in Theravance Biopharma by 0.6% in the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock valued at $16,112,000 after buying an additional 11,256 shares during the period. Finally, AQR Capital Management LLC bought a new position in Theravance Biopharma during the first quarter worth about $101,000. 99.10% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.